The FDA standardized bioequivalence administration protocols for generic chewable tablets, aligning product-specific guidance with harmonized international testing standards. The regulatory update aims to reduce variability in how bioequivalence studies are conducted for chewable oral solid dose forms. For generic manufacturers, the change can affect study planning, protocol design, and comparability expectations across product lines. It also signals continuing convergence between U.S. requirements and broader global approaches for common dosage forms. The FDA action focuses specifically on administration protocols, rather than efficacy endpoints, but can materially influence the operational burden and regulatory review pathway for sponsors.